NO20084481L - Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkompleks - Google Patents
Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkompleksInfo
- Publication number
- NO20084481L NO20084481L NO20084481A NO20084481A NO20084481L NO 20084481 L NO20084481 L NO 20084481L NO 20084481 A NO20084481 A NO 20084481A NO 20084481 A NO20084481 A NO 20084481A NO 20084481 L NO20084481 L NO 20084481L
- Authority
- NO
- Norway
- Prior art keywords
- receptor complex
- benzimidazole derivatives
- gabaa receptor
- modulating
- modulating gabaa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Denne oppfinnelsen vedrører nye benzimidazolderivater med formel (I), farmasøytiske preparater som inneholder disse forbindelsene, og fremgangsmåter for behandling med dem. Forbindelsene ifølge oppfinnelsen er anvendbare ved behandling av sentralnervesystemsykdommer og forstyrrelser som gir respons på modulering av GABA-reseptorkomplekset, og særlig for bekjempelse av angst og beslektede sykdommer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78527806P | 2006-03-24 | 2006-03-24 | |
DKPA200600426 | 2006-03-24 | ||
DKPA200601327 | 2006-10-12 | ||
US85128406P | 2006-10-13 | 2006-10-13 | |
PCT/EP2007/052766 WO2007110374A1 (en) | 2006-03-24 | 2007-03-22 | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084481L true NO20084481L (no) | 2008-12-18 |
Family
ID=39456294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084481A NO20084481L (no) | 2006-03-24 | 2008-10-23 | Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkompleks |
Country Status (27)
Country | Link |
---|---|
US (2) | US7902230B2 (no) |
EP (2) | EP2001855B1 (no) |
JP (1) | JP5260489B2 (no) |
KR (1) | KR20080111097A (no) |
CN (1) | CN101384559B (no) |
AR (1) | AR060084A1 (no) |
AT (1) | ATE486856T1 (no) |
AU (1) | AU2007229502B2 (no) |
BR (1) | BRPI0710203A2 (no) |
CA (1) | CA2647252A1 (no) |
CY (1) | CY1111603T1 (no) |
DE (1) | DE602007010261D1 (no) |
DK (1) | DK2001855T3 (no) |
ES (1) | ES2355163T3 (no) |
HK (1) | HK1132257A1 (no) |
HR (1) | HRP20100616T1 (no) |
IL (1) | IL192297A (no) |
MX (1) | MX2008010885A (no) |
MY (1) | MY149855A (no) |
NO (1) | NO20084481L (no) |
NZ (1) | NZ569438A (no) |
PL (1) | PL2001855T3 (no) |
PT (1) | PT2001855E (no) |
RU (1) | RU2435759C2 (no) |
SI (1) | SI2001855T1 (no) |
TW (1) | TWI391381B (no) |
WO (1) | WO2007110374A1 (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1877052B1 (en) | 2005-04-13 | 2009-07-22 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
PL1996556T3 (pl) | 2005-12-05 | 2010-05-31 | Neurosearch As | Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA |
TWI391381B (zh) * | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
AU2008345696A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth Llc | Benzimidazole compounds |
TW201029986A (en) * | 2008-11-14 | 2010-08-16 | Neurosearch As | Novel compounds |
WO2010055129A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
WO2010055130A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
TW201029987A (en) * | 2008-11-14 | 2010-08-16 | Neurosearch As | Novel compounds |
WO2010055133A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
TW201029989A (en) * | 2008-11-14 | 2010-08-16 | Neurosearch As | Novel compounds |
US8278460B2 (en) | 2009-10-15 | 2012-10-02 | Concert Pharmaceuticals, Inc. | Substituted benzimidazoles |
EP2903980B1 (en) * | 2012-10-01 | 2017-07-19 | F. Hoffmann-La Roche AG | Benzimidazoles as cns active agents |
CN107445845A (zh) * | 2017-08-24 | 2017-12-08 | 重庆沃肯精细化工有限公司 | 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1,2‑苯二胺的方法 |
BR112020016269A2 (pt) * | 2018-02-11 | 2020-12-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Reguladores derivados de esteroides, método para prepará- los e suas utilizações |
HUE060943T2 (hu) * | 2018-09-13 | 2023-04-28 | Saniona As | A gaba A receptor ligandum |
KR102219563B1 (ko) * | 2019-02-15 | 2021-02-24 | 에스티팜 주식회사 | 페나진 유도체 제조를 위한 중간체 및 그의 제조방법 |
CN115003301A (zh) * | 2019-10-23 | 2022-09-02 | 纽罗塞克医疗公司 | 用gabaa受体调节剂的癫痫状况的治疗 |
CN116693555A (zh) * | 2022-02-25 | 2023-09-05 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK40192D0 (da) * | 1992-03-26 | 1992-03-26 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
US5554630A (en) * | 1993-03-24 | 1996-09-10 | Neurosearch A/S | Benzimidazole compounds |
AU675484B2 (en) * | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
CA2218552C (en) * | 1995-04-21 | 2002-04-16 | Neurosearch A/S | Benzimidazole compounds and their use as modulators of the gabaa receptor complex |
KR100297445B1 (ko) | 1995-04-21 | 2001-10-25 | 페더 벨링 | 벤즈이미다졸화합물및감마-아미노부틸산수용체복합체의조절인자로서의그들의용도 |
EP0934281B1 (en) | 1996-10-21 | 2010-01-06 | Neurosearch A/S | 1-phenyl-benzimidazole compounds and their use as baga- a? receptor modulators |
EP1023286A1 (en) | 1997-10-10 | 2000-08-02 | Neurosearch A/S | Benzimidazole compounds, pharmaceutical compositions containing the compounds and their use |
EP1194410B1 (en) | 1999-06-22 | 2006-01-18 | Neurosearch A/S | Benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
US7335777B2 (en) * | 2003-04-03 | 2008-02-26 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the GABAA receptor complex |
JP2006522070A (ja) * | 2003-04-03 | 2006-09-28 | ニューロサーチ、アクティーゼルスカブ | ベンズイミダゾール誘導体及びこれをgabaa受容体複合体をモジュレートするために使用する方法 |
JP2008521903A (ja) * | 2004-12-01 | 2008-06-26 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | N置換されたベンズイミダゾリルC−kit阻害剤及びコンビナトリアルベンゾイミダゾールライブラリー |
US7809569B2 (en) | 2004-12-22 | 2010-10-05 | Enterprise Integration Group, Inc. | Turn-taking confidence |
EP1877052B1 (en) | 2005-04-13 | 2009-07-22 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
PL1996556T3 (pl) | 2005-12-05 | 2010-05-31 | Neurosearch As | Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA |
TWI391381B (zh) * | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
-
2007
- 2007-02-27 TW TW096106596A patent/TWI391381B/zh not_active IP Right Cessation
- 2007-03-22 US US12/279,511 patent/US7902230B2/en active Active
- 2007-03-22 ES ES07727240T patent/ES2355163T3/es active Active
- 2007-03-22 MX MX2008010885A patent/MX2008010885A/es active IP Right Grant
- 2007-03-22 DK DK07727240.9T patent/DK2001855T3/da active
- 2007-03-22 EP EP07727240A patent/EP2001855B1/en active Active
- 2007-03-22 EP EP10182058A patent/EP2319837B1/en active Active
- 2007-03-22 AU AU2007229502A patent/AU2007229502B2/en not_active Ceased
- 2007-03-22 MY MYPI20082972A patent/MY149855A/en unknown
- 2007-03-22 SI SI200730455T patent/SI2001855T1/sl unknown
- 2007-03-22 AT AT07727240T patent/ATE486856T1/de active
- 2007-03-22 PT PT07727240T patent/PT2001855E/pt unknown
- 2007-03-22 WO PCT/EP2007/052766 patent/WO2007110374A1/en active Application Filing
- 2007-03-22 NZ NZ569438A patent/NZ569438A/en not_active IP Right Cessation
- 2007-03-22 CA CA002647252A patent/CA2647252A1/en not_active Abandoned
- 2007-03-22 JP JP2009500873A patent/JP5260489B2/ja not_active Expired - Fee Related
- 2007-03-22 RU RU2008129868/04A patent/RU2435759C2/ru not_active IP Right Cessation
- 2007-03-22 KR KR1020087026085A patent/KR20080111097A/ko not_active Application Discontinuation
- 2007-03-22 PL PL07727240T patent/PL2001855T3/pl unknown
- 2007-03-22 DE DE602007010261T patent/DE602007010261D1/de active Active
- 2007-03-22 CN CN2007800059554A patent/CN101384559B/zh not_active Expired - Fee Related
- 2007-03-22 BR BRPI0710203-8A patent/BRPI0710203A2/pt not_active IP Right Cessation
- 2007-03-23 AR ARP070101206A patent/AR060084A1/es unknown
-
2008
- 2008-06-19 IL IL192297A patent/IL192297A/en not_active IP Right Cessation
- 2008-10-23 NO NO20084481A patent/NO20084481L/no not_active Application Discontinuation
-
2009
- 2009-09-10 HK HK09108282.1A patent/HK1132257A1/xx not_active IP Right Cessation
-
2010
- 2010-11-12 HR HR20100616T patent/HRP20100616T1/hr unknown
- 2010-12-09 CY CY20101101143T patent/CY1111603T1/el unknown
-
2011
- 2011-01-20 US US13/009,988 patent/US8288418B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084481L (no) | Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkompleks | |
NO20093009L (no) | Kondensert ring heterocykel kinase modulatorer | |
NO20070907L (no) | Pyrrolo-pyridin kinase modulatorer | |
NO20070908L (no) | Sammensmeltede ringheterocykelkinasemodulatorer | |
NO20090267L (no) | Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse | |
NO20080981L (no) | Nitrocatechol-derivater som COMT-inhibitorer | |
NO20083214L (no) | Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer | |
NO20074207L (no) | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders | |
NO20084374L (no) | Imidazoltiazolforbindelser for behandling av sykdom | |
NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
WO2007106236A3 (en) | Pyrrolo-pyridine kinase modulators | |
WO2009097287A9 (en) | Compounds and compositions as kinase inhibitors | |
NO20084567L (no) | Polymorfe former av (2S) - (4E) -N-metyl-5-(3-isopropoksypyridin)yl]-4-penten-2-amin for behandling av sykdommer i sentralnervesystemet | |
GEP20146101B (en) | Pyridine and pyrazine derivatives as protein kinase modulators | |
NO20090608L (no) | Tyrosinkinaseinhibitorer | |
NO20084489L (no) | Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet | |
NO20090266L (no) | Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer | |
WO2007042544A3 (en) | Imidazole derivatives and their use for modulating the gabaa receptor complex | |
NO20085031L (no) | Benzimidazolmodulatorer av VR1 | |
NO20065678L (no) | 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer. | |
ATE517106T1 (de) | Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren | |
NO20084792L (no) | Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer | |
NO20075793L (no) | Benzimidazolderivater og deres anvendelse for modulering av GABAA - reseptorkomplekset | |
NO20083045L (no) | Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkomplekset | |
NO20080553L (no) | Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |